The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations

The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations

TROP2, a transmembrane glycoprotein, is overexpressed and plays pivotal roles in diverse epithelial tumors. The differential expression of TROP2 between cancer and normal tissues offers distinct advantages in developing drugs targeting it. Thus, TROP2-targeted antibody-drug conjugates (ADCs), includ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Renwang Liu, Mingbiao Li, Penghu Gao, Xuanguang Li, Zihe Zhang, Jun Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Oncology
Subjects:	Trop2 antibody-drug conjugates lung cancer bioinformatics analysis molecular mechanism
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1638054/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rho-ROCK liberates sequestered claudin for rapid de novo tight junction formation
by: Yuma Cho, et al.
Published: (2025-07-01)

Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
by: Tian Xu, et al.
Published: (2023-12-01)

Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization
by: Henrike Barbara Zech, et al.
Published: (2025-05-01)

The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability
by: Sayumi Yamazoe, et al.
Published: (2025-08-01)

Radionuclide Drug Conjugates: China's 15-Year Research and Development Process and Latest Policy Support
by: LIU dan, et al.
Published: (2024-09-01)

THE RUDE DURYUDANA AND THE TRICKY SENGKUNI
by: Dyah Ayu Nila Khrisna
Published: (2016-01-01)

Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term
by: Felix Stader, et al.
Published: (2025-04-01)

GPP estimation based on CatBoost and analysis of change driving factors in Shanxi Province, China
by: Yujie Li, et al.
Published: (2025-07-01)

The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study
by: Miao He, et al.
Published: (2025-08-01)

Datopotamab deruxtecan induces hallmarks of immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-08-01)

Structural bioinformatics approaches for predicting novel drug targets in hepatitis C virus proteins: a comprehensive analysis
by: Miao Qu, et al.
Published: (2025-07-01)

Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models
by: Jianhua Gong, et al.
Published: (2020-01-01)

Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions
by: Fei Zhang, et al.
Published: (2025-05-01)

Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer
by: Edwin Lin, et al.
Published: (2025-07-01)

Enhancement of SARS-CoV-2 Receptor Binding Domain -CR3022 Human Antibody Binding Affinity via In silico Engineering Approach
by: Fatemeh Sefid, et al.
Published: (2021-09-01)

Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates
by: Tanu Dixit, et al.
Published: (2025-08-01)

Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
by: Isis Wolf, et al.
Published: (2025-01-01)

Performance prediction of electronic fan and water pump of engine cooling system based on joint simulation and machine learning
by: Yujin Zou, et al.
Published: (2025-05-01)

Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
by: Xu Chen, et al.
Published: (2025-07-01)

New treatment options for bladder cancer patients: based on ASCO 2022 materials and beyond
by: I. V. Zyatchin, et al.
Published: (2022-10-01)

Linker-GPT: design of Antibody-drug conjugates linkers with molecular generators and reinforcement learning
by: An Su, et al.
Published: (2025-07-01)

Promising therapeutic efficacy and safety of a novel integrin α6-targeting peptide-drug conjugate in lung adenocarcinoma
by: Wuyou Gao, et al.
Published: (2025-07-01)

TIGAR inhibits glucose-metabolism and cisplatin-chemosensitivity in human lung cancer cells
by: Yang Feng, et al.
Published: (2025-07-01)

Optimization of human TAT-Fab antibody expression and its bioactivity assay
by: WANG Qun, et al.
Published: (2007-11-01)

Une affaire trop sérieuse ?
by: Seppo Hentilä
Published: (2002-07-01)

Pressure sensing intelligent martial arts short soldier combat protection system based on conjugated polymer nanocomposite materials
by: Song Jinqiu, et al.
Published: (2025-08-01)

Fundamentals of protein interaction network mapping
by: Jamie Snider, et al.
Published: (2015-12-01)

Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications
by: Ruotong Shi, et al.
Published: (2025-08-01)

Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives
by: Dimitrios Papageorgiou, et al.
Published: (2025-06-01)

Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed
by: Meng Li-Fei, et al.
Published: (2025-06-01)

Developing angiogenesis-related prognostic biomarkers and therapeutic strategies in bladder cancer using deep learning and machine learning
by: Yutong Li, et al.
Published: (2025-07-01)

Reference-guided detection of the transcriptome reveals circular RNA-related competing endogenous RNA networks in response to three respiration pathogens in pig lungs
by: Qian Wu, et al.
Published: (2025-06-01)

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study
by: Yu Hua, et al.
Published: (2025-05-01)

Effect of Fluence Rate on Tumor Tissue Damage in IRDye700DX‐Based Photoimmunotherapy
by: Susumu Yamashita, et al.
Published: (2025-08-01)

Evaluation of the Effect of Radiotherapy Timing on Toxicity in HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine During the Adjuvant Period
by: İlknur Deliktaş Onur, et al.
Published: (2025-04-01)

Intratumor heterogeneity related signature for clinical outcome and immunotherapy advantages in lung adenocarcinoma
by: Yanhua Zuo, et al.
Published: (2025-03-01)

Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity
by: Yu Long, et al.
Published: (2025-08-01)

Therapeutic landscape of ovarian cancer: recent advances and emerging therapies
by: Ling Wang, et al.
Published: (2025-08-01)

Identification and analysis of the endoplasmic reticulum stress hub genes in sepsis-associated ARDS
by: Ling Gao, et al.
Published: (2025-08-01)

Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants
by: Lidia Cerdán, et al.
Published: (2025-12-01)